Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis

Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis

Abstract Background The aim of the study was to evaluate the cost-effectiveness of nivolumab plus chemotherapy as first-line treatment for patients with advanced gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma from the perspective of Chinese and US society. Methods To conduct...

Full description

Bibliographic Details
Main Authors: Peng-Fei Zhang, Xuan-Qiong Shi, Qiu Li
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Cost-effectiveness
Nivolumab
First-line
Gastric cancer
Markov model
Online Access:https://doi.org/10.1186/s12962-023-00476-2

Similar Items

Similar Items